In December 2024, IQVIA released a new white paper, developed in collaboration with GSK and GCOA, examining the significant economic and clinical burden of Respiratory Syncytial Virus (RSV) in older adults (age ≥60 years) across select high-income APEC countries, including China, Japan, South Korea, Canada, Singapore, New Zealand, Australia, Hong Kong, and Taiwan. The study…

Following the passage of the Inflation Reduction Act in 2022, healthcare systems in the United States are facing many changes in the name of saving costs and creating efficiencies. But do the benefits actually outweigh the costs?  GCOA’s issue brief, “Utilization Management Post-Inflation Reduction Act and the Threat to Healthy Aging,” addresses the unintended negative consequences…

Despite tremendous scientific innovation and the availability of advanced treatments, ageist systems, attitudes, and beliefs continue to place countless lives at unnecessary risk by preventing timely access to care and treatment. The paper shares evidence of ageism’s impact on health outcomes and system costs and outlines concrete steps for stakeholders to take in the fight…

On June 6, 2024, The Global Coalition on Aging (GCOA) Alliance for Health Innovation convened a roundtable discussion of cross-sectoral experts representing patients, caregivers, academia, biopharmaceutical innovators, and business communities to discuss Prescription Drug Affordability Boards (PDABs), Upper Payment Limits (UPLs), and the risk they pose to the innovation that is needed to safeguard healthy…

At the World Summit on the Information Society, May 30, 2024, GCOA hosted a panel discussion on the global health crisis that is AMR and how technology can, should and will have an impact through diagnostics, surveillance, and innovative developments.  AMR will be responsible for 10 million deaths annually by 2050 – on track to…